Valuation: Stoke Therapeutics, Inc.

Market Cap 1.71B 1.55B 1.43B 1.29B 2.44B 161B 2.52B 17.17B 6.82B 86.12B 6.43B 6.29B 274B P/E 2026 *
-6.58x
P/E 2027 * -6.37x
Enterprise Value 1.52B 1.38B 1.27B 1.15B 2.17B 143B 2.24B 15.28B 6.07B 76.62B 5.72B 5.6B 244B EV / Sales 2026 *
43.9x
EV / Sales 2027 * 29.3x
Free-Float
96.38%
Yield 2026 *
-
Yield 2027 * -
1 day-5.62%
1 week+0.50%
Current month-0.34%
1 month+8.49%
3 months-20.53%
6 months-19.36%
Current year-17.45%
1 week 26.14
Extreme 26.14
28.44
1 month 22.05
Extreme 22.05
28.44
Current year 22.05
Extreme 22.05
40.22
1 year 22.05
Extreme 22.05
40.22
3 years 3.77
Extreme 3.77
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 2025-03-18
Chief Tech/Sci/R&D Officer 54 2014-05-31
Director of Finance/CFO 49 2024-05-06
Director TitleAgeSince
Chairman 65 2015-06-30
Director/Board Member 67 2014-05-31
Director/Board Member 72 2015-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/2/26 Sell

Chief Technology Officer

-7,195 0.0112%
10/2/26 Sell

General Counsel

-627 0.0011%
10/1/26 Sell

Chief Technology Officer

-1,051 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-5.62%+0.50%+4.26%+515.02% 1.82B
+1.10%-2.67%+62.79%+70.47% 67.53B
+1.28%+8.71%+13.96%+95.16% 60.74B
+0.36%-0.95%+20.09%+99.04% 55.66B
-0.96%+7.41%+10.20%+108.91% 47.97B
-1.25%+2.35%+22.74%+38.34% 45.24B
-2.41%-0.73%+167.89%+794.72% 39.08B
+1.21%-2.56%+20.27%+52.81% 35.34B
-0.87%-2.89%+79.60%+63.96% 33.45B
-2.22%+8.56%-39.26%+397.14% 26.49B
Average -0.94%+2.99%+36.25%+223.56% 41B
Weighted average by Cap. -0.19%+3.38%+40.24%+168.23%

Financials

2026 *2027 *
Net sales 34.72M 31.4M 28.98M 26.23M 49.5M 3.26B 50.98M 348M 138M 1.74B 130M 128M 5.55B 50.69M 45.84M 42.31M 38.3M 72.27M 4.77B 74.43M 508M 202M 2.55B 190M 186M 8.11B
Net income -264M -239M -220M -200M -377M -24.83B -388M -2.65B -1.05B -13.27B -991M -970M -42.25B -298M -269M -249M -225M -425M -28B -437M -2.98B -1.19B -14.97B -1.12B -1.09B -47.64B
Net Debt -189M -171M -158M -143M -269M -17.77B -278M -1.89B -753M -9.5B -709M -694M -30.23B -228M -206M -191M -173M -326M -21.47B -335M -2.29B -909M -11.48B -857M -839M -36.53B
Projected Income Statement - Annual - Stoke Therapeutics, Inc.
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
26-11-12 US$26.20 -5.62% 501,150
26-11-11 US$27.76 +2.02% 836,813
26-11-10 US$27.21 -1.80% 838,276
26-11-09 US$27.71 +4.41% 1,059,985
26-11-06 US$26.54 +1.80% 1,162,631
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Stoke Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.20USD
Average target price
46.38USD
Spread / Average Target
+77.04%
  1. Stock Market
  2. Stocks
  3. STOK Stock